DAVEY, Richard T., Jr.
New Engl. J. Med., 381, 2293-2303, 2019.
Order of authorship in the original publication: Mulangu, Dodd, Davey.... One synthetic drug (Remdesivir, an antiviral) and 3 biologicals were used in this trial. The 3 biologicals were: REGN-EB3, a triple monoclonal antibody biologic, and Mab114, a single monoclonal antibody biologic, and ZMapp, another triple monoclonal antibody biologic. REGN-EB3, and Mab114 outperformed the other two, reducing mortality from up to 90% in the untreated to 33.5% for the REGN group and 35.1% for the Mab114 group. This was the first randomized, controlled trial of biopharmaceuticals that had significant success in curing Ebola. Digital text from nejm.org at this link.
(Thanks to Juan Weiss for this reference and its interpretation.)
Subjects: INFECTIOUS DISEASE › Ebola Virus Disease, PHARMACOLOGY › PHARMACEUTICALS › Antiviral Drugs, PHARMACOLOGY › PHARMACEUTICALS › Biological Medical Product (Biologic), WOMEN, Publications by › Years 2000 -